Here, we report that drug repurposing of the clinically available BAFF-neutralizing antibody belimumab, which is approved for treatment of SLE, re-sensitized primary CLL cells to the small molecule inhibitors idelalisib, ibrutinib and venetoclax. Here, TNFSF13B is linked to systemic lupus erythematosus.